Araris Biotech AG, a AU ZH, Switzerland-based antibody-drug conjugate company, raised $24M in funding.
The round was co-led by 4BIO Capital, and Pureos Bioventures, with participation from Wille AG, Follicular Lymphoma Innovation, VI Partners, Schroders Capital, btov Partners and Redalpine. Damir Illich, Ph.D. from Wille AG and Sophie Allauzen, Ph.D. from the Institute for Follicular Lymphoma Innovation will also be joining the Araris team as board observers.
The company intends to use the funds to support the further development and advancement of its antibody-drug conjugate candidates, created using the proprietary linker technology, as they move closer towards clinical development.
Led by CEO Philipp Spycher, Ph.D., Araris Biotech is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs. The company is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.
FinSMEs
04/10/2022